fashion -WSS

fashion

author：leisure time 2025-08-06 05:21:33 - browse：39

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Goldman Sachs launches $650M fund for life science investments

WSS

Videos point to link between seizures and unexplained toddler deaths

The FDA must approve intranasal treatments for anaphylaxis

340B reform proposal comes out of Senate working group

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Readout Newsletter: Amgen, Regeneron, BGI Group and more

3 medical device trends to watch in 2024

entertainment

fashion

entertainment

Malaria cases in Florida and Texas: Here’s what you need to know

J&J to buy cancer drug developer Ambrx Biopharma

Malaria cases in Florida and Texas: Here’s what you need to know

Gene therapy for Afghan refugees’ infant will be fully covered

Drug repurposing or repositioning? The language matters

3 medical device trends to watch in 2024

BioMarin wins approval for gene therapy to treat hemophilia A

A single drug, study failures leave Anavex with nothing but cash

Jerome Adams on the need for new antivirals for Covid

Adopting new red light myopia treatments may be short

focus

A single drug, study failures leave Anavex with nothing but cash

Updated Covid vaccine has 54% effectiveness, new study suggests

Ahead of JPM, here's who's profiting most in health care

New weight loss drugs work. But how can they best be used?

Adopting new red light myopia treatments may be short

AdventHealth escalates lawsuit against insurance vendor Multiplan

focus

focus

hotspot

knowledge